90% of US Adults Have CKM Syndrome — A New Framework Maps the Path to Reversal
Cardiovascular-kidney-metabolic syndrome affects nearly all US adults. A staged intervention model offers a roadmap from early risk to advanced disease.
Summary
Cardiovascular-kidney-metabolic (CKM) syndrome — the dangerous overlap of metabolic dysfunction, chronic kidney disease, and cardiovascular disease — now affects an estimated 90% of US adults. A 2023 American Heart Association staging framework classifies CKM from stage 0 (no risk) to stage 4 (full clinical CVD). Stage 2, marked by metabolic risk factors or early kidney disease, is the most common, affecting nearly half of Western adults. Each stage transition meaningfully raises cardiovascular mortality. The review maps the biological chain from excess body fat and insulin resistance to kidney and heart damage, highlights the underappreciated role of fatty liver disease, and outlines stage-matched treatments — from GLP-1 agonists and lifestyle change early on to SGLT2 inhibitors and RAAS blockade in advanced disease. Early intervention is key to breaking the cycle.
Detailed Summary
Cardiovascular-kidney-metabolic (CKM) syndrome has emerged as one of the most consequential frameworks in modern medicine, reframing what were once treated as separate conditions — obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease — as a single, interconnected disease process. The scale of the problem is staggering: an estimated 90% of US adults fall somewhere on the CKM spectrum.
This review, authored by researchers at AstraZeneca and Lund University, synthesizes the epidemiology, pathophysiology, and staged management of CKM using the American Heart Association's 2023 four-stage classification. Stage 0 represents no metabolic risk; stage 4 is established cardiovascular disease with persistent metabolic dysfunction. Stage 2 — defined by the presence of metabolic risk factors or early chronic kidney disease — is the most prevalent, affecting nearly half of adults in Western populations. Critically, 34% of stage 1 individuals progress to a higher stage, with each transition conferring incrementally greater cardiovascular mortality risk.
The biological architecture of CKM centers on a self-reinforcing cycle: dysfunctional adipose tissue drives insulin resistance, which triggers endothelial dysfunction, renal injury, and cardiac remodeling. The review gives particular attention to the bidirectional organ crosstalk — where kidney damage worsens cardiac outcomes and vice versa — and elevates the role of metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH) as underrecognized accelerants of the syndrome.
Intervention strategies are stage-specific. Early-stage disease is best addressed through lifestyle modification and weight-loss pharmacotherapy, particularly GLP-1 receptor agonists and dual GLP-1/GIP agonists. Advanced disease warrants aggressive cardiorenal protection using SGLT2 inhibitors and renin-angiotensin-aldosterone system (RAAS) blockade, drug classes with strong evidence for reducing mortality and slowing organ damage.
For longevity-focused readers, CKM syndrome represents the dominant pathway by which metabolic dysfunction shortens healthspan. The staged framework enables targeted, earlier intervention — precisely the model needed to preserve cardiovascular and renal function into older age. This summary is based on the abstract only.
Key Findings
- An estimated 90% of US adults are affected by CKM syndrome at some stage of the spectrum.
- Stage 2 CKM — metabolic risk factors or early kidney disease — is the most prevalent, affecting nearly half of Western adults.
- 34% of stage 1 individuals progress to a higher stage, with each transition raising cardiovascular mortality risk.
- Fatty liver disease (MASLD/MASH) is an emerging and underappreciated driver of CKM progression.
- GLP-1 agonists suit early-stage CKM; SGLT2 inhibitors and RAAS blockade are the cornerstones of advanced-stage management.
Methodology
This is a narrative review article published in the American Journal of Physiology — Cell Physiology. The authors synthesize population-based epidemiological data, mechanistic research, and clinical trial evidence organized around the AHA's 2023 four-stage CKM classification framework. No primary data were collected; findings represent a synthesis of existing literature.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. As a narrative review rather than a systematic review or meta-analysis, it is subject to selection bias in the literature synthesized. The epidemiological prevalence figure of 90% is drawn from US adult data and may not generalize to other populations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: